Search research articles
Contact Us
Filters
Showing results (401-410 of 703) with videos related to
Page
of 71
Sort By:
CA: a Cancer Journal for Clinicians
|
October 14, 2017
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, et al.
Journal for Immunotherapy of Cancer
|
December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G V Long, A Arance, L Mortier, et al.
Nature Medicine
|
November 13, 2023
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
Itske Fraterman, Irene L M Reijers, Petros Dimitriadis, et al.
Nature Medicine
|
June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
The Oncologist
|
November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma
Jeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 7, 2013
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma
Paolo A Ascierto, David Minor, Antoni Ribas, et al.
Melanoma Research
|
May 17, 2022
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread
Andrew T Li, Jia Miin Yip, Harsham Choksi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
Page
of 71
Search research articles
Search
Showing results (401-410 of 703) with videos related to
Sort By:
Page
of 71
CA: a Cancer Journal for Clinicians
|
October 14, 2017
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, et al.
Journal for Immunotherapy of Cancer
|
December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G V Long, A Arance, L Mortier, et al.
Nature Medicine
|
November 13, 2023
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
Itske Fraterman, Irene L M Reijers, Petros Dimitriadis, et al.
Nature Medicine
|
June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
The Oncologist
|
November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma
Jeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 7, 2013
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma
Paolo A Ascierto, David Minor, Antoni Ribas, et al.
Melanoma Research
|
May 17, 2022
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread
Andrew T Li, Jia Miin Yip, Harsham Choksi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
Page
of 71